Pharmacy Website
    Clinic Website

    Intelligence » Lymphoma » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    New trial results suggest CAR-T effects are durable in lymphoma

    Monday, June 18, 2018 -- Novartis and Celgene/Juno release longer term data on important lymphoma indication at EHA

    Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis

    Tuesday, June 19, 2018 -- by Xiaojuan Gao, Jia Li, Yaqi Wang, Shuai Liu, Baohong Yue Recent studies show that Epstein-Barr virus (EBV) positivity might be related to adverse prognosis in patients with diffuse large B-cell lymphoma (DLBCL), but the results are still inconclusive. We conducted this meta-analysis to define the clinical value of EBV infection in DLBCL. All potential articles in PubMed, Web of Science, Medline, and Embase were retrieved. Using the random-effects or fixed-effect model, pooled hazard ratios (HRs) or relative risk (RR) with 95% confidence intervals (CIs) were used to calculate the correlation between EBER and prognosis and clinical features in DLBCL. A total of 13 qualified studies with 4111 patients were identified in our meta-analysis based on the inclusion and

    TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma

    Thursday, June 21, 2018 -- Tumors accumulate high levels of mutant p53 (mutp53), which contributes to mutp53 gain-of-function properties. The mechanisms that underlie such excessive accumulation are not fully understood. To discover regulators of mutp53 protein accumulation, we performed a large-scale RNA interference screen in a Burkitt lymphoma cell line model. We identified transformation/transcription domain-associated protein (TRRAP), a constituent of several histone acetyltransferase complexes, as a critical positive regulator of both mutp53 and wild-type p53 levels. TRRAP silencing attenuated p53 accumulation in lymphoma and colon cancer models, whereas TRRAP overexpression increased mutp53 levels, suggesting a role for TRRAP across cancer entities and p53 mutations. Through clustered regularly interspaced short palindromic repeats (CRISPR)–Cas9 screening, we identified a 109-amino-acid region in the N-terminal HEAT repeat region

    CELGENE CORPORATION: Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel (JCAR017) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO

    Wednesday, June 20, 2018 -- Celgene Corporation (NASDAQ:CELG) today announced updated six-month safety and efficacy data from the TRANSCEND (NHL-001) study of lisocabtagene maraleucel (liso-cel; JCAR017), an investigational CD19-directed CAR T cell therapy, in patients with relapsed/refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (NHL) in a presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Read more..

    ABBVIE: AbbVie Announces U.S. FDA Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab as a Fixed Duration Treatment for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Have Received One Prior Therapy

    Wednesday, June 20, 2018 -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has approved, under priority review, VENCLEXTA® (venetoclax tablets) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy Read more..

    MERCK: FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Refractory or Relapsed Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

    Wednesday, June 20, 2018 -- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S.Food and Drug Administration (FDA) has approved KEYTRUDA®, the company’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. Read more..

    Trillium Doses First Patient with TTI-622, a Candidate for Treating Myeloma, Lymphoma

    Wednesday, June 20, 2018 -- Trillium Therapeutics recently dosed the first patient in its Phase 1 clinical trial of TTI-622, a checkpoint inhibitor of the immune system being developed for the treatment of relapsed or refractory lymphoma and myeloma. Although the innate immune system is a key ally in fighting cancer, tumor cells may learn to evade immune attacks by activating “hiding” […] The post Trillium Doses First Patient with TTI-622, a Candidate for Treating Myeloma, Lymphoma appeared first on Myeloma Research News.

    R-THP-COP a New Therapeutic Alternative for Diffuse Large B Cell Lymphoma

    Monday, June 18, 2018 -- Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.

    Non-Hodgkin lymphoma patients on bendamustine face increased risk for common infections

    Monday, June 18, 2018 -- In patients with indolent non-Hodgkin lymphoma, or iNHL, treatment with bendamustine is associated with an increased risk for common and opportunistic infections compared with other chemotherapy regimens, researchers reported in Clinical Infectious Diseases.“Bendamustine is a potent chemotherapy agent increasingly used to treat [iNHL],” wrote Monica Fung, MD clinical fellow in infectious diseases at the University of California, San Francisco, and colleagues. “While effective, it causes significant T-cell lymphopenia, which may increase risk of infection. We examined

    Lymphoma Risk with JAK Inhibitors for MPNs

    Monday, June 18, 2018 -- (MedPage Today) -- Preexisting aberrant B-cell clone implicated